Advertisement

Rheumatology International

, Volume 13, Issue 4, pp 135–138 | Cite as

Influence of dichloromethylene diphosphonate on reactive oxygen species production by human neutrophils

  • R. Serretti
  • P. Core
  • S. Muti
  • F. Salaffi
Originals

Summary

Biphosphonates suppress bone destruction in various diseases. Several studies have demonstrated the potential use of biphosphonates in arthritis. The results of these studies indicate that the effectiveness of the biphosphonates, for inhibiting the arthritic process, is related to their antiresorptive properties. It has been shown that the generation of reactive oxygen species is associated with the formation of new osteoclasts and enhanced bone resorption. We studied the effects of the dichloromethylene diphosphonate on the reactive oxygen species production by activated polymorphonuclear leucocytes, measured by chemiluminescence. Our results indicate a dose-dependent inhibitory effect of dichloromethylene diphosphonate on reactive oxygen species production by polymorphonuclear leucocytes stimulated with N-formil-methionyl-leucyl-phenylalanine, the calcium ionophore A23187 and phorbol myristate acetate. The mechanisms by which this biphosphonate inhibits the reactive oxygen species production by activated polymorphonuclear leucocytes are discussed.

Key words

Dichloromethylene diphosphonate Polymorphonuclear leukocytes Reactive oxygen species Chemiluminescence 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bonjour JP, Rizzoli R (1990) Clodronate in hypercalcemia of malignancy. Calcif Tissue Int 46:20–25Google Scholar
  2. 2.
    Ryan PJ, Sherry M, Gibson T, Fogelman I (1992) Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1-biphosphonate (APD). Br J Rheumatol 31:97–101Google Scholar
  3. 3.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw J, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79Google Scholar
  4. 4.
    Fleisch H, Russell RGG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264Google Scholar
  5. 5.
    Fleisch H (1987) Experimental basis for the use of biphosphonates in Paget's disease of bone. Clin Orthop 21:72–78Google Scholar
  6. 6.
    Francis MD, Hovanick K, Boyce RW (1989) Inhibition by a biphosphonate of the adjuvant arthritis process. J Bone Mineral Res 3:S135Google Scholar
  7. 7.
    Delaisse JM, Eeckhouty Y, Vaes G (1985) Biphosphonates and bone resorption: effects on collagenase and lysosomal enzyme excretion. Life Sci 37:2291–2296Google Scholar
  8. 8.
    Miller SC, Jee WSS (1979) The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Rec 193:439–463Google Scholar
  9. 9.
    Ross Garrett I, Boyce BF, Oreffo ROC, Bonewald L, Poser J, Mundy GR (1990) Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 85:632–639Google Scholar
  10. 10.
    Root RK, Metcalf JA (1977) H2O2 release from human granulocytes during phagocytosis: relationship to superoxide anion formation and cellular catabolism of H2O2: studies with normal and cytochalasin B treated cells. J Clin Invest 60:1266–1279Google Scholar
  11. 11.
    Weissmann G, Smolen JE, Korchak HM (1980) Release of inflammatory mediators from stimulated neutrophils. N Engl J Med 303:27–34Google Scholar
  12. 12.
    Hyvönen PM, Kowolik MJ (1992) Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study. Ann Rheum Dis 51:203–209Google Scholar
  13. 13.
    Ferrante A, Thong YH (1978) A rapid one-step procedure for purification of mononuclear and polymorphonuclear leucocytes from human blood using a modification of the hypaqueficoll technique. J Immunol Methods 24:389–393Google Scholar
  14. 14.
    Ferrante A, Thong YH (1980) Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human periferal blood by the hypaque-ficoll method. J Immunol Methods 36:109–117Google Scholar
  15. 15.
    Ferrante A, Thong YH (1982) Separation of mononuclear and polymorphonuclear leucocytes from human blood by the hypaque-ficoll method is dependent of blood column height. J Immunol 48:81–85Google Scholar
  16. 16.
    Allegrezza-Giulietti A, Serretti R, Beccerica E, Muti S, Ferretti G, Cervini C (1991) Platelet release products modulate some aspects of polymorphonuclear leukocytes activation. J Cell Biochem 47:242–250Google Scholar
  17. 17.
    Conrad KA, Lee SM (1981) Clodronate kinetics and dynamics. Clin Pharmacol Ther 30:114–120Google Scholar
  18. 18.
    Gay JC, Lukens JN, English DK (1984) Differential inhibition of neutrophil superoxide generation by non-steroidal antiinflammatory drugs. Inflammation 8:209–222Google Scholar
  19. 19.
    Crapo JD, McCord JM, Fridowich I (1978) Preparation and assay of superoxide dismutases. In: Colowick SP, Kaplan NO (eds) Methods in enzymology, vol 53. Academic Press, New York, pp 382–387Google Scholar
  20. 20.
    Deby C, Pincemail J (1986) Toxicitè de l'oxigene, radicaux libres et moyens de defense. Presse Méd 15:1468–1474Google Scholar
  21. 21.
    Rossi F (1986) The O 2 forming NADPH oxidase of the phagocytes: nature, mechanism of activation and function. Biochem Biophys Acta 853:65–89Google Scholar
  22. 22.
    Armitage P (1971) Statistical methods in medical research. Blackwell Scientific, OxfordGoogle Scholar
  23. 23.
    Reynolds JJ, Minkin C, Morgan DB, Spycher D, Fleisch H (1972) The effect of two diphosphonates on the resorption of mouse calvaria in vitro. Calcif Tissue Res 10:302–313Google Scholar
  24. 24.
    Russel RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H (1970) The influence of pyrophosphate, condensed phosphate and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcif Tissue Res 6:183–186Google Scholar
  25. 25.
    Fleisch H (1988) Biphosphonates: a new class of drugs in disease of bone and calcium metabolism. In: Baker PF (ed) Handbook of experimental pharmacology, vol 83. Springer, Berlin Heidelberg New York, pp 441–466Google Scholar
  26. 26.
    Schenk R, Merz WA, Muhlbauer RC, Russel RGG, Fleisch H (1973) Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196–214Google Scholar
  27. 27.
    Flanagan AM, Chambers TJ (1989) Dichloromethylenebisphosphonate (Cl2MDP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MDP-coated bone. Bone Miner 6:33–43Google Scholar
  28. 28.
    Boonekamp PM, Wee-Pals LJA van der, Wijk-von Lennep MML van, Thesing CW, Bijvoet OLM (1986) Two modes of action of bisphosphonates on osteoclastis resorption of mineralized matrix. Bone Miner 1:27–39Google Scholar
  29. 29.
    Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC (1990) Biphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456–461Google Scholar
  30. 30.
    Flora L (1979) Comparative anti-inflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 22:304–346Google Scholar
  31. 31.
    Francis MD, Hovanick K, Boyce RW (1989) NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tiss Reac 11:239–252Google Scholar
  32. 32.
    Staite ND, Aspar DG, Dunn CJ, Galinet LA, Wu H, Essani NA, Nugent RA, Schacter ST, Rohloff NA, Smith RJ (1993) Novel bisphosphonate esters with both anti-inflammatory and anti-arthritic activity. Clin Exp Rheumatol 11:S-191 (abstract 24)Google Scholar
  33. 33.
    Ferraccioli GF, Salaffi F, Carotti M, Cervini C, Baroli E (1993) Cl2MDP improves rheumatoid inflammation. In: 5th INWIN, Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, Geneva, Switzerland, 25–28 April 1993 (abstract 208)Google Scholar
  34. 34.
    Freund M, Pick E (1986) The mechanism of action of lymphokines. IX. The enzymatic basis of hydrogen production by lymphokine-activated macrophages. J Immunol 137:1312–1318Google Scholar
  35. 35.
    Recklies AD, Golds EE (1992) Induction of synthesis and release of interleukine-8 from human articular chondrocytes and cartilage explants. Arthritis Rheum 35:1510–1519Google Scholar
  36. 36.
    Endo H, Akahoshi T, Takagishi K, Kashiwazaki S, Matsushima K (1991) Elevation of interleukin-8 (IL-8) levels in joints fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res 10:245–252Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • R. Serretti
    • 1
  • P. Core
    • 1
  • S. Muti
    • 1
  • F. Salaffi
    • 1
  1. 1.Department of RheumatologyUniversity of AnconaItaly

Personalised recommendations